Variants of Toll-Like Receptor 4 Modify the Efficacy of Statin Therapy and the Risk of Cardiovascular Events
S. Matthijs Boekholdt(Amsterdam Neuroscience), J. Wouter Jukema(Leiden University Medical Center), Ron J.G. Peters(Amsterdam UMC Location University of Amsterdam), Aeilko H. Zwinderman(Amsterdam Neuroscience), Pieter H. Reitsma(Leiden University Medical Center), John J.P. Kastelein(QRx Pharma (United States)), Ernst E. van der Wall(Leiden University Medical Center), Willem R.P. Agema(Leiden University Medical Center)
Cited by 226
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews
|Journal of Clinical Epidemiology|2005|3.3k